CK Life Sciences (00775) announced the establishment of Shunpu Pharmaceutical Technology Co., Ltd., focusing on promoting the development of its therapeutic cancer vaccine combinations.

CK Life Sciences (00775) announced the establishment of its wholly-owned subsidiary Sequencio Therapeutics Company Limited ("Sequencio"), focused on advancing the development of its therapeutic cancer vaccine combinations. The establishment of Sequencio allows the company to integrate its therapeutic cancer vaccine research projects into a dedicated platform, reflecting the company's strategy to expand in the emerging field of cancer immunotherapy. Sequencio focuses on developing therapeutic vaccines that activate the patient's own immune system to fight cancer cells, aiming to achieve long-lasting and stable disease remission while maintaining good safety, thereby addressing key limitations of existing standard therapies. Sequencio bears a long-term vision - to reshape the cancer treatment model, moving from guiding temporary tumor shrinkage towards achieving long-term controlled remission through the immune system. Vaccine development and design will be carried out by an in-house team, in collaboration with external partners, to accelerate overall development progress. Sequencio's preclinical combination includes the company's experimental cancer vaccine targeting TROP2 (Trophoblast cell-surface antigen 2). In preclinical studies on breast cancer and colorectal cancer in mice, this candidate vaccine successfully induced strong T cell immune responses and completely (100%) inhibited tumor growth. Additionally, this combination also includes candidate vaccines targeting Preferentially Expressed Antigen in Melanoma (PRAME), programmed cell death ligand 1 (PD-L1), B7-H3 immune checkpoint, and Claudin 6 protein. With the ownership of Sequencio, TransCode, and Dogwood, the company has established a research and development platform with a diverse portfolio covering both early and late-stage projects, focusing on areas where current medical needs are not fully met.